Results 61 to 70 of about 10,308 (152)

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation

Haematologica, 2006
Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions.
M Weisser, J Tischer, S Schnittger, C Schoch, G Ledderose, HJ Kolb   +5 more
doaj  

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia

Haematologica, 2003
We report a chronic myeloid leukemia (CML) patient in chronic phase (CP) who developed blast crisis (BC) under imatinib mesylate administered in a dose reduced and non-continuous fashion because of hematologic intolerance.
PB Staber, R Brezinschek, W Linkesch, H Sill, P Neumeister   +4 more
doaj  

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

Терапевтический архив, 2010
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease.
Ol'ga Veniaminovna Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva, O V Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva   +7 more
doaj  

Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia

Eurasian Journal of Medicine, 2011
Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak, Harika Celebi, Aynur Albayrak, Esra Saribacak Can, Vedat Aslan, Birgul Onec, Ipek Coban   +6 more
doaj  

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate. [PDF]

Gels, 2023
Jitrangsri K, Khaing EM, Intaraphairot T, Phaechamud T, Mahadlek J.   +4 more
europepmc   +1 more source

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. [PDF]

Int J Mol Sci, 2023
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, Agostinelli C, Sabattini E, Orsatti A, Ferrari A, Capirossi G, Servili C, Ghelli Luserna di Rorà A, Martinelli G, Simonetti G, Rosti G.   +15 more
europepmc   +1 more source

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Brazilian Journal of Pharmaceutical Sciences
Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic ...
Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres   +4 more
doaj   +1 more source

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate. [PDF]

Cureus, 2023
Batra J, Ankireddypalli AR, Kanugula AK, Gorle S, Kaur J.   +4 more
europepmc   +1 more source

Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy. [PDF]

Clin Case Rep, 2022
D'Addona M, Pezzullo L, Giudice V, Serio B, Baldi C, Zeppa P, Selleri C.   +6 more
europepmc   +1 more source